Editorial: Trajectory of soluble programmed cell death protein‐1 and ligand‐1 in HBV‐infected individuals treated with pegylated interferon—Implications for stopping rules and the HBV cure programme. Authors' reply

Chan Xie
DOI: https://doi.org/10.1111/apt.18174
IF: 9.524
2024-07-19
Alimentary Pharmacology & Therapeutics
Abstract:LINKED CONTENT This article is linked to Chen et al papers. To view these articles, visit https://doi.org/10.1111/apt.18131 and https://doi.org/10.1111/apt.18142
pharmacology & pharmacy,gastroenterology & hepatology
What problem does this paper attempt to address?